Authors

Nancy L. Saccone, Washington University School of Medicine
Robert C. Culverhouse, Washington University School of Medicine
Tae-Hwi Schwantes-An, Washington University School of Medicine
Dale S. Cannon, University of Utah School of Medicine
Xiangning Chen, Virginia Commonwealth UniversityFollow
Sven Cichon, Research Center Jülich
Ina Giegling, University of Munich
Shizhong Han, Yale University School of Medicine
Younghun Han, University of Texas M. D. Anderson Cancer Center
Kaisu Keskitalo-Vuokko, University of Helsinki
Xiangyang Kong, GlaxoSmithKline
Maria T. Landi, National Institutes of Health
Jennie Z. Ma, University of Virginia
Susan E. Short, Brown University
Sarah H. Stephens, University of Colorado
Victoria L. Stevens, American Cancer Society
Lingwei Sun, Washington University School of Medicine
Yufei Wang, Institute of Cancer Research
Angela S. Wenzlaff, Wayne State University
Steven H. Aggen, Virginia Commonwealth UniversityFollow
Naomi Breslau, Michigan State University
Peter Broderick, Institute of Cancer Research, Sutton Surrey
Nilanjan Chatterjee, National Institutes of Health
Jingchun Chen, Virginia Commonwealth UniversityFollow
Andrew C. Heath, Washington University School of Medicine
Marku Heliovaara, National Institute for Health and Welfare
Nicole R. Hoft, University of Colorado
David J. Hunter, Harvard School of Public Health
Majken K. Jensen, Harvard School of Public Health
Nicholas G. Martin, Queensland Institute of Medical Research
Grant W. Montgomery, Queensland Institute of Medical Research
Tianhua Niu, University of Virginia
Thomas J. Payne, he University of Mississippi Medical Center
Leena Peltonen, National Institute for Health and Welfare
Michele L. Pergadia, Washington University School of Medicine
John P. Rice, Washington University School of Medicine
Richard Sherva, Boston University School of Medicine
Margaret R. Spitz, University of Texas M. D. Anderson Cancer Center
Juzhong Sun, American Cancer Society
Jen C. Wang, Washington University School of Medicine
Robert B. Weiss, University of Utah School of Medicine
William Wheeler, Information Management Services
Stephanie H. Witt, Central Institute of Mental Health Mannheim
Bao-Zhu Yang, Yale University School of Medicine
Neil E. Caporaso, National Institutes of Health
Marissa A. Ehringer, University of Colorado, Boulder
Tim Eisen, Cambridge Biomedical Research Centre
Susan M. Gapstur, American Cancer Society
Joel Gelemter, Yale University School of Medicine
Richard Houlston, Sutton Surrey
Jaakko Kaprio, University of Helsinki
Kenneth S. Kendler, Virginia Commonwealth UniversityFollow
Peter Kraft, Harvard School of Public Health
Mark F. Leppert, University of Utah School of Medicine
Ming D. Li, University of Virginia
Pamela A. F. Madden, Washington University School of Medicine
Markus M. Nothen, University of Bonn
Sreekumar Pillai, Roche Pharmaceuticals
Marcella Rietschel, Central Institute of Mental Health Mannheim
Dan Rujescu, University of Munich
Ann Schwartz, Wayne State University
Christopher I. Amos, University of Texas M. D. Anderson Cancer Center
Laura J. Bierut, Washington University School of Medicine

Document Type

Article

Original Publication Date

2010

Journal/Book/Conference Title

PLOS Genet

Volume

6

DOI of Original Publication

10.1371/journal.pgen.1001053

Comments

Originally Published at http://dx.doi.org/10.1371/journal.pgen.1001053

Date of Submission

November 2014

Abstract

Recently, genetic association findings for nicotine dependence, smoking behavior, and smoking-related diseases converged to implicate the chromosome 15q25.1 region, which includes the CHRNA5-CHRNA3-CHRNB4 cholinergic nicotinic receptor subunit genes. In particular, association with the nonsynonymous CHRNA5 SNP rs16969968 and correlates has been replicated in several independent studies. Extensive genotyping of this region has suggested additional statistically distinct signals for nicotine dependence, tagged by rs578776 and rs588765. One goal of the Consortium for the Genetic Analysis of Smoking Phenotypes (CGASP) is to elucidate the associations among these markers and dichotomous smoking quantity (heavy versus light smoking), lung cancer, and chronic obstructive pulmonary disease (COPD). We performed a meta-analysis across 34 datasets of European-ancestry subjects, including 38,617 smokers who were assessed for cigarettes-per-day, 7,700 lung cancer cases and 5,914 lung-cancer-free controls (all smokers), and 2,614 COPD cases and 3,568 COPD-free controls (all smokers). We demonstrate statistically independent associations of rs16969968 and rs588765 with smoking (mutually adjusted p-valuesCHRNA5 in brain and lung tissue.

Rights

This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.

Is Part Of

VCU Psychiatry Publications

142323.zip (2438 kB)

Share

COinS